| Indicators | Browse All

Caribou Biosciences, Inc. (CRBU)

Healthcare | Biotechnology | Berkeley, United States | NasdaqGS
1.62 USD -0.04 (-2.410%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 1.65 +0.03 (1.852%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 2:15 a.m. EDT

The investment case here is fundamentally broken. This biotech stock has suffered a catastrophic multi-year decline, dropping nearly 94% over the last four years with every single year showing negative returns. The company is burning cash aggressively, reporting negative free cash flow and operating cash flow, while revenue has contracted significantly. Despite a 'strong buy' analyst rating and a lofty $32 price target, these metrics reflect a speculative bet on a future cure rather than a viable business today; the market has correctly priced the high risk of total capital loss. The balance sheet, while currently liquid, cannot sustain this burn rate indefinitely without dilution or a successful clinical trial. Short-term, the stock is trapped between the $1.50 support and the heavy put wall at $2.00, likely to remain range-bound or drift lower until a binary event occurs. There is no margin of safety here, only a lottery ticket with a very low probability of success.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.168166
MSTL0.182982
AutoARIMA0.189356
AutoTheta0.193283

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 41%
H-stat 2.11
Ljung-Box p 0.000
Jarque-Bera p 0.564
Excess Kurtosis -0.35
Attribute Value
Sector Healthcare
Debt to Equity Ratio 27.171
Revenue per Share 0.104
Market Cap 173,676,176
Forward P/E -1.28
Beta 2.28
Website https://cariboubio.com

As of Aug. 22, 2026, 2:15 a.m. EDT: Speculators are positioning for a continued grind lower, evidenced by heavy put open interest at the $2.00 strike across multiple expirations, which acts as a significant resistance wall. While there is some call volume at $2.50, the overwhelming majority of open interest sits out-of-the-money on the downside side, suggesting a 'bear put spread' mentality rather than a bullish breakout attempt. Implied volatility remains elevated relative to deep ITM strikes, indicating fear of further downside moves.


Info Dump

Attribute Value
52 Week Change -0.13829786
Address1 2,929 7th Street
Address2 Suite 105
All Time High 32.645
All Time Low 0.66
Ask 1.63
Ask Size 1
Average Daily Volume10 Day 967,740
Average Daily Volume3 Month 1,758,993
Average Volume 1,758,993
Average Volume10Days 967,740
Beta 2.276
Bid 1.2
Bid Size 2
Book Value 0.926
City Berkeley
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.62
Current Ratio 6.487
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 1.66
Day Low 1.6
Debt To Equity 27.171
Display Name Caribou Biosciences
Earnings Timestamp End 1,794,427,200
Earnings Timestamp Start 1,794,427,200
Ebitda -104,609,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.841
Enterprise To Revenue 8.771
Enterprise Value 88,017,168
Eps Current Year -1.175
Eps Forward -1.26333
Eps Trailing Twelve Months -1.05
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.6667
Fifty Day Average Change -0.0467
Fifty Day Average Change Percent -0.02801944
Fifty Two Week Change Percent -13.829785
Fifty Two Week High 3.535
Fifty Two Week High Change -1.9150001
Fifty Two Week High Change Percent -0.54172564
Fifty Two Week Low 1.38
Fifty Two Week Low Change 0.24000001
Fifty Two Week Low Change Percent 0.17391305
Fifty Two Week Range 1.38 - 3.535
Financial Currency USD
First Trade Date Milliseconds 1,627,047,000,000
Float Shares 102,908,492
Forward Eps -1.26333
Forward P E -1.2823253
Free Cashflow -59,605,500
Full Exchange Name NasdaqGS
Full Time Employees 97
Fullday Change -0.04
Fullday Change Percent -2.40964
Fullday Price 1.65
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -73,818,000
Has Pre Post Market Data 1
Held Percent Insiders 0.082440004
Held Percent Institutions 0.44852
Implied Shares Outstanding 107,207,513
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-07-23
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Long Name Caribou Biosciences, Inc.
Market us_market
Market Cap 173,676,176
Market State CLOSED
Max Age 86,400
Message Board Id finmb_272189231
Most Recent Quarter 1,782,777,600
Net Income To Common -103,403,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 177,428,434
Number Of Analyst Opinions 7
Open 1.66
Operating Cashflow -95,780,000
Operating Margins -16.90394
Payout Ratio 0.0
Phone 510 982 6030
Post Market Change 0.029999971
Post Market Change Percent 1.85185
Post Market Price 1.65
Post Market Time 1,787,959,806
Previous Close 1.66
Price Eps Current Year -1.3787235
Price Hint 4
Price To Book 1.7494601
Price To Sales Trailing12 Months 17.307043
Profit Margins 0.0
Quick Ratio 6.357
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.04
Regular Market Change Percent -2.40964
Regular Market Day High 1.66
Regular Market Day Low 1.6
Regular Market Day Range 1.6 - 1.66
Regular Market Open 1.66
Regular Market Previous Close 1.66
Regular Market Price 1.62
Regular Market Time 1,787,947,201
Regular Market Volume 666,306
Return On Assets -0.36845002
Return On Equity -0.78266
Revenue Growth -0.438
Revenue Per Share 0.104
Sand P52 Week Change 0.20204377
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 107,207,513
Shares Percent Shares Out 0.1163
Shares Short 12,465,346
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 11,594,287
Short Name Caribou Biosciences, Inc.
Short Percent Of Float 0.120699994
Short Ratio 9.79
Source Interval 15
State CA
Symbol CRBU
Target High Price 32.0
Target Low Price 4.0
Target Mean Price 11.85714
Target Median Price 10.0
Total Cash 112,314,000
Total Cash Per Share 1.048
Total Debt 26,655,000
Total Revenue 10,035,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.05
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.80405
Two Hundred Day Average Change -0.18404996
Two Hundred Day Average Change Percent -0.102020435
Type Disp Equity
Volume 666,306
Website https://cariboubio.com
Zip 94,710